JCM
ELDN icon

Jacobi Capital Management’s Eledon Pharmaceuticals ELDN Stock Holding History

Jacobi Capital Management’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3
Closed – – 658
2021
Q3 		$0 Buy
+3
New +$21 ﹤0.01% 1449

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobi Capital Management's ELDN Position: Q4 2021 in Review

Jacobi Capital Management sold out of Eledon Pharmaceuticals (ELDN) in Q4 2021, closing a stake of 3 shares.

Jacobi Capital Management first reported a position in ELDN in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 36 funds tracked by Wall St. Rank hold ELDN as of Q4 2021.

  • Jacobi Capital Management reported no remaining Eledon Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Jacobi Capital Management sold 3 Eledon Pharmaceuticals shares in Q4 2021.
  • Jacobi Capital Management first reported a position in Eledon Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • Jacobi Capital Management's Eledon Pharmaceuticals position peaked at $0 in Q3 2021.
  • 36 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q4 2021.

Based on Jacobi Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.